Niraparib plus bevacizumab versus niraparib alone for platinum-sensitive recurrent ovarian cancer (NSGO-AVANOVA2/ENGOT-ov24): a randomised, phase 2, superiority trial

SummaryBackgroundPlatinum-based chemotherapy is the foundation of treatment for platinum-sensitive recurrent ovarian cancer, but has substantial toxicity. Bevacizumab and maintenance poly(ADP-ribose) polymerase (PARP) inhibitors both significantly improve efficacy versus standard therapy, primarily...

Full description

Saved in:
Bibliographic details
Volume: 20
Main Author: Mirza, Mansoor Raza, MD
Åvall Lundqvist, Elisabeth, PhD
Birrer, Michael J, Prof
dePont Christensen, Rene, PhD
Nyvang, Gitte-Bettina, MD
Malander, Susanne, PhD
Anttila, Maarit, PhD
Werner, Theresa L, MD
Lund, Bente, MD
Lindahl, Gabriel, MD
Hietanen, Sakari, PhD
Peen, Ulla, MD
Dimoula, Maria, MD
Roed, Henrik, DMSci
Ør Knudsen, Anja, MD
Staff, Synnöve, PhD
Krog Vistisen, Anders, MD
Bjørge, Line, Prof
Mäenpää, Johanna U, Prof
Format: Journal Article
Language: English
Place of publication: NEW YORK Elsevier Ltd 2019
ELSEVIER SCIENCE INC
published in: The lancet oncology Vol. 20; no. 10; pp. 1409 - 1419
Related: AVANOVA investigators
AVANOVA Investigators
ORCID: 0000-0002-0240-2770
0000-0003-4734-4743
Data of publication: 2019
ISSN: 1470-2045
1474-5488
1474-5488
EISSN: 1474-5488
Discipline: Medicine
Subjects:
Online Access: available in Bonn?
Database: Web of Knowledge
Web of Science - Science Citation Index Expanded - 2019
Science Citation Index Expanded
Web of Science
PubMed
CrossRef
MEDLINE - Academic
OpenAIRE
SwePub
Database information Databases - DBIS